Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease

@article{Choi2015ErratumAP,
  title={Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin{\textregistered} in Patients with Type 1 Gaucher Disease},
  author={Jin-Ho Choi and Beom Hee Lee and Jung min Ko and Young Bae Sohn and Jin-Sung Lee and Gu-Hwan Kim and Sun-Hee Heo and June-Young Park and Yoo Mi Kim and Ja-Hye Kim and Han-Wook Yoo},
  journal={Journal of Korean Medical Science},
  year={2015},
  volume={30},
  pages={1373 - 1373}
}
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. pISSN 1011-8934 eISSN 1598-6357 http://dx.doi.org/10.3346/jkms.2015.30.9.1373 • J Korean Med Sci 2015; 30: 1373 CORRESPONDENCE 

Topics from this paper

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
TLDR
This book aims to provide a chronology of key events and institutions that have contributed to the development of encephalopathy in children over a period of 40 years.
Recent advances and future challenges in Gaucher disease.